Follow us on Twitter
twitter icon@FreshPatents


Killer Cells patents

      

This page is updated frequently with new Killer Cells-related patent applications.




 Modified natural killer cells having anti-fugetactic properties and uses thereof patent thumbnailModified natural killer cells having anti-fugetactic properties and uses thereof
This invention provides ex vivo methods for making modified natural killer cell compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof.. .
The General Hospital Corporation Dba Massachusetts General Hospital


 Development of natural killer cells and functional natural killer cell lines patent thumbnailDevelopment of natural killer cells and functional natural killer cell lines
The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines.
University Of Utah Research Foundation


 Modified natural killer cells and uses thereof patent thumbnailModified natural killer cells and uses thereof
The present invention provides, in certain aspects, a natural killer (nk) cell that expresses all or a functional portion of interleukin-15 (il-15), and methods for producing such cells. The invention further provides methods of using a natural killer (nk) cell that expresses all or a functional portion of interleukin-15 (il-15) to treat cancer in a subject or to enhance expansion and/or survival of nk cells..
St. Jude Children's Research Hospital, Inc.


 In vivo priming of natural killer cells patent thumbnailIn vivo priming of natural killer cells
The disclosure concerns a method for cancer treatment by in vivo priming and activation of natural killer cells for achieving tumor cell lysis. The method includes introducing into a patient a priming tumor cell preparation (ptcp) derived from a first tumor cell line, which is irradiated to inactivate the first tumor cells or a membrane preparation thereof, the first tumor cells having known priming ligands on the membrane surface thereof.
Immune Ventures Llc


 Methods of generating natural killer cells patent thumbnailMethods of generating natural killer cells
Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the nk cells produced by the method to an individual having the cancer or viral infection..
Anthrogenesis Corporation


 Modified natural killer cells, compositions and uses thereof patent thumbnailModified natural killer cells, compositions and uses thereof
Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.. .
Fullhope Biomedical Co., Ltd.


 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells patent thumbnailTumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells..
Anthrogenesis Corporation


 3d adcc nk facs assay patent thumbnail3d adcc nk facs assay
Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format..
Hoffmann-la Roche Inc.


 Natural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation patent thumbnailNatural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation
The invention provides natural killer cells and improved methods for increasing natural killer cell viability, proliferation and cytotoxicity following cryopreservation.. .

 Development of natural killer cells and functional natural killer cell lines patent thumbnailDevelopment of natural killer cells and functional natural killer cell lines
The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines.

Formulation and preparing specific t cell, and preparing the formulation

The present invention provides a formulation and method for preparing specific t cells, and a method for fabricating the formulation is also disclosed. The formulation can induce specific t cell responses, and comprises at least a cell population of dendritic killer cells presenting specific antigens.
Fullhope Biomedical Co., Ltd.

Cytokine derived treatment with reduced vascular leak syndrome

The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an il-15 derivative conjugate so as to induce a proliferation of natural killer cells (nk cells) which is the same or higher than the one obtained with high dose of interleukin-2 (hdil-2); eventually associated with a pharmaceutically acceptable carrier.. .
Institut Gustave Roussy (igr)

Method for treating cancers with dendritic killer cells and pharmaceutical composition comprising the same

The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is il-15.
Fullhope Biomedical Co., Ltd

Natural killer cells from placenta

Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
Anthrogenesis Corporation

Method of providing cellular therapy using modified natural killer cells or t lymphocytes

A method of decreasing cytokine production and release is disclosed. In one embodiment, the method comprises the step of providing cytotoxic cells to a subject wherein the cells are preferably natural killer cells or t lymphocytes and are genetically modified to express a chimeric antigen receptor comprising a first element that is an extracellular antigen receptor and a second intracellular element that is a signaling moiety comprising altered adap-dependent or fyn-dependent signaling such that downstream signaling causing cytokine release is decreased.
Bloodcenter Research Foundation

Natural killer cells and uses thereof

Provided herein are methods of producing natural killer (nk) cells and nk progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of nk cells and nk progenitor cell populations using a three-step expansion and differentiation method.
Anthrogenesis Corporation

Industrial preparation of natural killer cells (nks) and injection using human allo-geneic karyocytes

Disclosed is an industrial preparation of natural killer cells (nks) and an injection using human allogeneic karyocytes comprising: using umbilical cord blood and peripheral blood from legitimate sources as raw materials, obtaining stem cells by a method for extracting and separating karyocytes, or using ficoll or percoll density gradient centrifugation to isolate and screen out karyocytes; diluting the above-mentioned karyocytes with cell culture medium, adding interferon, interleukin, cd3 antibody, and human albumin, loading them together into a bioreactor for perfusion culture, and then performing multiplication culture; the passage number of natural killer cells from multiplication culture is no less than 8, and the culture time is no less than 4 weeks; the markers of the natural killer cells obtained after the multiplication culture are cd3−\cd56+, cd16+, cd57+, and cd8+, wherein cd16+/cd56+≧15%, cd3−/cd56+≧50%, and cd8+/cd57+≧8%; then preparing an injection with a certain concentration using the cell suspension obtained by above-mentioned method.. .

Medicament for wound treatment

The invention relates to stathmin, stathmin, a nucleic acid encoding said stathmin or a cell expressing stathmin for use in the treatment of chronic wounds or disease- or medication-dependent impaired wound healing in a patient or for increasing or inducing the proliferation and/or migration of mesenchymal cells, of stem cells, for stimulating immune cells, preferably natural killer cells, for stimulating fibroblasts, for stimulating epithelial cells, preferably epithelial cells of the epidermis, or for stimulating angiogenesis.. .
Simu Trade Consulting Gmbh & Co. Leasing Kg

Methods and compositions for natural killer cells

The application provides new compositions and methods for stimulating the production of natural killer (nk) cells in a subject. Nk cells can be selectively expanded with a combination of stimulating ligands.
University Of Central Florida Research Foundation, Inc.

Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells

The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated jurkat cells and irradiated epstein-barr virus transformed lymphocyte continuous line (ebv-lcl) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells..
Korea University Research And Business Foundation

Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

This invention provides methods of generating natural killer (nk) cells and dendritic cells (dcs). The methods utilize human hemangioblasts as intermediate cells to generate the nk cells and dcs.
Stem Cell & Regenerative Medicine International, Inc.

Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same

The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “nk cells”), nk cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing nk cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration.
Green Cross Labcell

Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation

A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. Suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients.
Otsuka Pharmaceutical Factory, Inc.

Methods of generating natural killer cells

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the nk cells produced by the method to an individual having the cancer or viral infection..
Anthrogenesis Corporation

Method for inducing proliferation of natural killer cells by mobile nanomatrices

The present invention provides an in-vitro method for inducing proliferation of nk cells, the method comprising contacting a population of nk cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains; and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide activation signals to the nk cells; thereby activating and inducing the nk cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices.
Miltenyi Biotec Gmbh

Epigenetic marker for the identification of natural killer cells

The present invention relates to a method, in particular an in vitro method for identifying a subgroup of natural killer cells of a mammal, preferably cd3−, non t-lymphocyte derived nk cells, which often express the surface proteins cd56 and/or cd16, comprising analyzing the accessibility of the genomic dna for osbpl, such as osbpl5, to bisulfite conversion and/or the methylation status of at least one cpg position in the genes for osbpl, such as osbpl5, in particular in their upstream and/or downstream regulatory regions, the promoter, introns, exons and introns exon borders and other conserved regions of said genes, wherein an increase of the accessibility of the genomic dna and/or a demethylation in the sample as analyzed is indicative for said subgroup of nk cells. The analyses according to the invention can identify cd56+ cells and distinguish them from all other cells such as, for example, either cd56− and/or cd56 bright cells.

Natural killer cell formulations

A formulation of supplement is able to boost the natural cells, both increasing the population of the natural cells and enhancing the natural cell's activity. The formulation can be administered via different forms, such as tablet, injection, skin absorption and etc.

Natural killer cell lines and methods of use

This invention relates to a natural killer cell line termed nk-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of nk-92.

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells..

Reversible immortalization

A gene complex for reversibly immortalizing cells contains an immortalizing gene region, which possesses at least a resistance gene, an immortalizing gene and, preferably, a suicide gene, and also two sequences which flank the gene region and which function as recognition sites for homologous intramolecular recombination, and at least one promoter located upstream of the gene region. A gene complex for imnomodulating cells contains a first immunomodulating gene region, whose expression inhibits the function of mhc i molecules, a second immunomodulating gene region, whose expression leads to the inactivation of natural killer cells, and a resistance gene.

Method for activating natural killer cells by tumor cell preparation in vitro

The present invention provides a method for activating a natural killer (nk) cell by contacting the nk cell in vitro with an activating tumour cell preparation (atcp). The invention also provides an activated nk cell produced by such a method and its use in the treatment of cancer..

Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells

The present invention relates generally to methods to prepare nk and lti-like, nk22 cells from hscs and uses of those cells.. .

Formulation for cultivating dendritic killer cells and method using the same

A formulation and method for cultivating dendritic killer cells is disclosed in the present invention. The formulation comprises an effective amount of at least one cytokine and the abovementioned cytokine is il-15.

Method for identifying and screening dendritic killer cells

A method for identifying and screening dendritic killer cells (dkc) is disclosed in the present invention, and the method is to identify a plurality of cell surface markers selected from a group consisting of hla-g−, cd14−, cd3-, cd19−, cd56dim and hla-dr+. The method for screening dkc from human peripheral blood mononuclear cells (pbmc) comprises the following steps.

Formulation and preparing specific t cell, and preparing the formulation

The present invention provides a formulation and method for preparing specific t cells, and a method for fabricating the above formulation is also disclosed. The formulation can induce specific t cell responses and comprises at least a cell population of dendritic killer cells presenting specific antigens.

Method for treating cancers with dendritic killer cells and pharmaceutical composition

The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is il-15.



Killer Cells topics:
  • Killer Cells
  • Natural Killer Cell
  • Allogeneic
  • Immunoglobulin
  • Stem Cells
  • Immunomodulator
  • Recombinant
  • Infectious Disease
  • Infectious
  • Lactobacillus
  • Lactobacillus Paracasei
  • Immunoglobulin A
  • Monoclonal
  • Polyclonal
  • Intravenous


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Killer Cells for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Killer Cells with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.367

    file did exist - file did put1725

    3 - 1 - 36